Hong Kong Stock Movement
LAEKNA-B rose by 15.25%. There has been no significant news recently; trading is active, and capital flow is evident. Considering the sector and industry trends, the stock shows significant volatility, and the specific reasons need further observation. no_news
Stocks with High Trading Volume in the Industry
Kangfang Biotech rose by 5.14%. Based on recent key news:
<ol>
<li>
On November 27, the National Healthcare Security Administration announced that the new version of the medical insurance drug catalog and the commercial insurance innovative drug catalog will be released soon, expected to go live in Guangzhou on the first weekend of December. This policy is expected to promote rapid volume growth for innovative drugs, benefiting Kangfang Biotech as one of the innovative drug companies, leading to a rise in stock price. Source: Announcement from the National Healthcare Security Administration
</li>
<li>
On November 26, the Hang Seng Medical ETF focuses on innovative drugs and related industries, with Kangfang Biotech as one of the innovative targets. Benefiting from the advantages of the Hong Kong Stock Exchange's 18A system, the market's expectation for its value reassessment has increased, driving the stock price up. Source: Announcement from the Hang Seng Medical ETF
</li>
<li>
On November 25, the FDA exempted LY03017 from the single-dose escalation trial phase in Phase I clinical trials. Luye Pharma plans to advance multiple indications in clinical trials. Although this news is not directly related to Kangfang Biotech, it shows a positive development trend in the innovative drug field, indirectly boosting market confidence. Source: Daily Economic News
</li>
</ol>
Innovent Biologics rose by 1.84%. Based on recent key news:
<ol>
<li>
On November 24, Innovent Biologics was included in the Hang Seng Index constituent stocks, leading to a rise in stock price. The Hang Seng Index Company announced that Innovent Biologics will become a constituent stock, increasing the number of constituent stocks to 89, pushing the stock price up by 4.4%, with a trading volume of HKD 285 million. Source: Zhitong Finance
</li>
<li>
On November 25, the application for the high-dose 9mg of Xinermu® for obese patients was accepted. Innovent Biologics announced that its new drug Xinermu® has been accepted by the National Medical Products Administration of China, which is expected to bring new market opportunities for the company, leading to a stock price increase of 1.96%. Source: Caihua News
</li>
<li>
On November 24, analysts maintained a buy rating for Innovent Biologics. Credit Suisse maintained a buy rating for Innovent Biologics, adjusting the target price to HKD 120, reflecting the market's confidence in its future growth. Source: Economic Information Daily
</li>
</ol>
BeiGene fell by 0.49%. Based on recent news:
<ol>
<li>
On November 25, BeiGene recorded a cross-trade of 250,000 shares at a price of HKD 206.3 per share, which is 1.9% lower than the previous closing price, resulting in a stock price drop of 1.7%. The transaction amount was HKD 518 million, with dominant buying capital of HKD 69.63 million. Source: Economic Information Daily
</li>
<li>
On November 27, the National Healthcare Security Administration announced that the new version of the basic medical insurance drug catalog and the first version of the commercial insurance innovative drug catalog will be released in December. Innovative drugs are expected to rapidly increase in volume, benefiting BeiGene as an innovative drug company. Source: Announcement from the National Healthcare Security Administration
On November 24th, BeiGene's full-year revenue guidance for 2025 is between USD 5.1 billion and USD 5.3 billion, with a gross margin expected to be in the range of 80% to 90%. The stock price has recently pulled back from a high of CNY 229.4, falling below the 10-day moving average. Source: Economic Information Daily. The innovative drug sector has entered a phase of &#34;revenue growth + profit leap.&#34;
</li>
</ol>
Stocks ranked among the top in market capitalization in the industry
Kanglongda Biotech-B rose by 0.49%. Based on recent key news:
<ol>
<li>
On November 27th, Kanglongda Biotech-B's core product, Lukanasatuzumab, is accelerating its global development process, with domestic commercialization imminent. CITIC Securities has set a target price of HKD 592, maintaining a &#34;Buy&#34; rating. This news has driven the stock price up.
</li>
<li>
On November 25th, a JP Morgan report indicated that Kanglongda Biotech's SKB264 has successfully completed Phase III clinical trials for first-line treatment of non-small cell lung cancer and plans to submit a supplemental new drug application. JP Morgan raised the target price to HKD 545 and reiterated an &#34;Overweight&#34; rating, boosting market confidence.
</li>
<li>
On November 24th, Kanglongda Biotech announced that its TROP2ADC Lukanasatuzumab combined with Pembrolizumab Phase III clinical study achieved its primary endpoint, becoming the first ADC combined with immune checkpoint inhibitors to yield positive results in the first-line NSCLC field globally, further validating the potential of combination therapy. The biopharmaceutical sector has been active recently, with significant capital inflows
</li>
</ol>

02105

LAEKNA-B rose 15.25%; CanSino Biologics rose 5.14%, with a transaction volume of HKD 1.006 billion; Innovent Biologics rose 1.84%, with a transaction volume of HKD 825 million; BeiGene fell 0.49%, with a transaction volume of HKD 515 million; Kelun-Biotech rose 0.49%, with a market value of HKD 106.2 billion

Hong Kong Stock Movement: LAEKNA-B surged 15.25%, with active capital flow attracting market attention